Related references
Note: Only part of the references are listed.Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure
Kenji Inoue et al.
INTERNATIONAL OPHTHALMOLOGY (2018)
Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4%
Etsuko Terao et al.
CURRENT EYE RESEARCH (2017)
One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension
Hidenobu Tanihara et al.
ACTA OPHTHALMOLOGICA (2016)
Species differences in metabolism of ripasudil (K-115) are attributed to aldehyde oxidase
Tomoyuki Isobe et al.
XENOBIOTICA (2016)
Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Shino Sato et al.
ADVANCES IN THERAPY (2016)
Ocular Penetration and Pharmacokinetics of Ripasudil Following Topical Administration to Rabbits
Tomoyuki Isobe et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2016)
Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma A Systematic Review and Network Meta-analysis
Tianjing Li et al.
OPHTHALMOLOGY (2016)
Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells
Yoshio Kaneko et al.
SCIENTIFIC REPORTS (2016)
RhoA GTPase-Induced Ocular Hypertension in a Rodent Model Is Associated with Increased Fibrogenic Activity in the Trabecular Meshwork
Padmanabhan P. Pattabiraman et al.
AMERICAN JOURNAL OF PATHOLOGY (2015)
Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial
David F. Garway-Heath et al.
LANCET (2015)
Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost A Report of 2 Randomized Clinical Trials
Hidenobu Tanihara et al.
JAMA OPHTHALMOLOGY (2015)
Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Hidenobu Tanihara et al.
ACTA OPHTHALMOLOGICA (2015)
p38 MAP Kinase Inhibitor Suppresses Transforming Growth Factor-β2-Induced Type 1 Collagen Production in Trabecular Meshwork Cells
Miyuki Inoue-Mochita et al.
PLOS ONE (2015)
Effects of K-115, a Rho-Kinase Inhibitor, on Aqueous Humor Dynamics in Rabbits
Tomoyuki Isobe et al.
CURRENT EYE RESEARCH (2014)
Ripasudil: First Global Approval
Karly P. Garnock-Jones
DRUGS (2014)
Shear Stress-Triggered Nitric Oxide Release From Schlemm's Canal Cells
Nicole E. Ashpole et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
Phase 2 Randomized Clinical Study of a Rho Kinase Inhibitor, K-115, in Primary Open-Angle Glaucoma and Ocular Hypertension
Hidenobu Tanihara et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2013)
Phase 1 Clinical Trials of a Selective Rho Kinase Inhibitor, K-115
Hidenobu Tanihara et al.
JAMA OPHTHALMOLOGY (2013)
Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Kang Zhang et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
A Practical Synthesis of (S)-tert-Butyl 3-Methyl-1,4-diazepane-1-carboxylate, the Key Intermediate of Rho-Kinase Inhibitor K-115
Noriaki Gomi et al.
SYNTHESIS-STUTTGART (2012)
Involvement of RhoA/Rho-Associated Kinase Signal Transduction Pathway in Dexamethasone-Induced Alterations in Aqueous Outflow
Tomokazu Fujimoto et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
The Effect of Rho-Associated Protein Kinase Inhibitor on Monkey Schlemm's Canal Endothelial Cells
Takanori Kameda et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2012)
A PRACTICAL SYNTHESIS OF NOVEL RHO-KINASE INHIBITOR, (S)-4-FLUORO-5-(2-METHYL-1,4-DIAZEPAN-1-YLSULFONYL)- ISOQUINOLINE
Noriaki Gomi et al.
HETEROCYCLES (2011)
Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers
Hidenobu Tanihara et al.
ARCHIVES OF OPHTHALMOLOGY (2008)
Development of specific Rho-kinase inhibitors and their clinical application
M Tamura et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway
Y Sasaki et al.
PHARMACOLOGY & THERAPEUTICS (2002)
Share Paper
